CP
ADMA icon

CenterBook Partners’s ADMA Biologics ADMA Stock Holding History

CenterBook Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$806K Buy
+89,467
New +$1.41M 0.04% 390
2025
Q3 		– Sell
-87,721
Closed -$1.6M – 548
2025
Q2 		$1.6M Buy
+87,721
New +$1.79M 0.09% 258
2022
Q4 		– Sell
-23,779
Closed -$58K – 372
2022
Q3 		$58K Buy
+23,779
New +$57K 0.01% 386

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

CenterBook Partners's ADMA Position: Q1 2026 in Review

CenterBook Partners opened a new position in ADMA Biologics (ADMA) in Q1 2026: 89,467 shares worth $806K. The stake represents 0.04% of the portfolio and ranks #390 among its holdings. This is a return to the name: CenterBook Partners previously reported a position in ADMA as recently as Q2 2025.

CenterBook Partners first reported a position in ADMA in Q3 2022 and has held it in 3 quarters since. The position peaked at $1.6M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • CenterBook Partners held 89,467 shares of ADMA Biologics worth $806K as of Q1 2026.
  • ADMA Biologics was a new CenterBook Partners position in Q1 2026.
  • ADMA Biologics made up 0.04% of CenterBook Partners's portfolio in Q1 2026, its #390 holding.
  • CenterBook Partners first reported a position in ADMA Biologics in Q3 2022 and has held it in 3 quarters since.
  • CenterBook Partners's ADMA Biologics position peaked at $1.6M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on CenterBook Partners's 13F filing for Q1 2026, filed 5 May 2026.